Soufflé Therapeutics closed an oversubscribed $135 million Series B led by Juvia Group to advance its lead clinical programs and pipeline.
- Amount
- $135M
- Stage
- Series B
- Announced
- 13 October 2026
- Lead
- Juvia Group
- Other investors
- TCG Crossover Management, BB Biotech, Fidelity Management & Research Company, Balyasny Asset Management
- Use of funds
- Advance lead clinical programs and continued pipeline progress.
- Checked
- Announced by the company